Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Manages OA. 1.2 Rheumatoid Arthritis (RA). ANDA 210628, held by Pharmazone. Celecoxib.
As of Nov 15, 2026, ANDA 210628 (Celecoxib), held by Pharmazone, was first approved by FDA on Nov 27, 2019, with 2 approved supplements and 0 published complete response letters.
First approved: Nov 27, 2019
Review: Standard
Supplements approved: 2
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
1. INDICATIONS AND USAGE Celecoxib capsule are indicated Celecoxib capsules are nonsteroidal anti-inflammatory drug indicated for:
Osteoarthritis (OA)
Rheumatoid Arthritis (RA)
Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older
Ankylosing Spondylitis (AS)
Acute Pain (AP)
Primary Dysmenorrhea (PD) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA. 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA. 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older. 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS. 1.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters